Cumberland Pharmaceuticals Inc Total Liabilities
Cumberland Pharmaceuticals Inc total liabilities. Based on the latest financial reports, Cumberland Pharmaceuticals Inc (CPIX) has total liabilities worth $45.77 Million USD as of June 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check CPIX asset liquidity ratio to evaluate the company's liquid asset resilience ratio.
Total Liabilities of Cumberland Pharmaceuticals Inc (2005–2025)
Total liabilities of Cumberland Pharmaceuticals Inc from 2005 to 2025. This chart illustrates how Cumberland Pharmaceuticals Inc's total liabilities have evolved over time, based on quarterly financial data. Explore CPIX long-term asset investment ratio to see how much of total assets are deployed in long-term investments.
Cumberland Pharmaceuticals Inc Competitors by Total Liabilities
The table below lists competitors of Cumberland Pharmaceuticals Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Quest For Growth - Pricaf
BR:QFG
|
Belgium | €51.99K |
|
Evergreen Corp
NASDAQ:EVGR
|
USA | $11.69 Million |
|
Cedergrenska AB
ST:CEDER
|
Sweden | Skr392.30 Million |
|
Mawana Sugars Limited
NSE:MAWANASUG
|
India | Rs5.98 Billion |
|
Garo AB
ST:GARO
|
Sweden | Skr475.60 Million |
|
Heranba Industries Limited
NSE:HERANBA
|
India | Rs13.33 Billion |
|
Safe Pro Group Inc.
NASDAQ:SPAI
|
USA | $1.56 Million |
|
Ascot Resources Ltd.
TO:AOT
|
Canada | CA$417.06 Million |
Liability Composition Analysis (2005–2025)
This chart breaks down Cumberland Pharmaceuticals Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see Cumberland Pharmaceuticals Inc total assets.
Liquidity & Leverage Metrics
Cumberland Pharmaceuticals Inc Total Liabilities Ratios Explained
Cumberland Pharmaceuticals Inc total liabilities ratios compare its liabilities with its current assets, cash and shareholder equity.
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 0.96 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 2.62 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.73 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Cumberland Pharmaceuticals Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Cumberland Pharmaceuticals Inc (2005–2025)
The table below shows the annual total liabilities of Cumberland Pharmaceuticals Inc from 2005 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | $52.28 Million | -1.43% |
| 2024-12-31 | $53.04 Million | +0.99% |
| 2023-12-31 | $52.52 Million | -7.79% |
| 2022-12-31 | $56.95 Million | +36.06% |
| 2021-12-31 | $41.86 Million | -15.59% |
| 2020-12-31 | $49.59 Million | -7.25% |
| 2019-12-31 | $53.46 Million | -6.41% |
| 2018-12-31 | $57.12 Million | +94.89% |
| 2017-12-31 | $29.31 Million | +44.50% |
| 2016-12-31 | $20.28 Million | +34.34% |
| 2015-12-31 | $15.10 Million | +3.05% |
| 2014-12-31 | $14.65 Million | +76.07% |
| 2013-12-31 | $8.32 Million | -36.12% |
| 2012-12-31 | $13.03 Million | +2.71% |
| 2011-12-31 | $12.68 Million | -11.55% |
| 2010-12-31 | $14.34 Million | -54.49% |
| 2009-12-31 | $31.50 Million | +132.25% |
| 2008-12-31 | $13.56 Million | +11.43% |
| 2007-12-31 | $12.17 Million | -20.73% |
| 2006-12-31 | $15.36 Million | +289.76% |
| 2005-12-31 | $3.94 Million | -- |
About Cumberland Pharmaceuticals Inc
Cumberland Pharmaceuticals Inc., a specialty pharmaceutical company, focuses on the acquisition, development, and commercialization of prescription products. The company offers Acetadote, an injection for the treatment of acetaminophen poisoning; Caldolor, an injection for the treatment of pain and fever; Kristalose, a prescription laxative oral solution for the treatment of constipation; Sancuso… Read more